Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 1, 2017, Pages 102-107

  Sawicki, Lino M ^a   Buchbender, Christian ^a   Boos, Johannes ^a   Giessing, Markus ^a   Ermert, Johannes ^b   Antke, Christina ^a   Antoch, Gerald ^a   Hautzel, Hubertus ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Gallium 68; PET CT; PSMA; Renal cell carcinoma

Indexed keywords

IODINATED CONTRAST MEDIUM; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; GLUTEUS MUSCLE; HUMAN; IMAGE ANALYSIS; IMAGING SOFTWARE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LUNG METASTASIS; MALE; MUSCLE METASTASIS; PET-CT SCANNER; PRIMARY TUMOR; WHOLE BODY CT; WHOLE BODY PET; DIAGNOSTIC IMAGING; FEMALE; KIDNEY TUMOR; MIDDLE AGED; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SECRETION (PROCESS); SENSITIVITY AND SPECIFICITY; VERY ELDERLY; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 84961249482     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3360-2     Document Type: Article

References (10)

1. Lara PN, Jonasch E. Kidney cancer: principles and practice. Berlin: Springer; 2012.
2. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9:461–73. doi:10.3233/cbm-2011-0176.
3. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995–4000. doi:10.1200/jco.2003.04.073.
4. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103:615–9. doi:10.1111/j.1464-410X.2008.08150.x.
5. Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90. doi:10.1016/j.urology.2007.03.025.
6. Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology. 2001;57:801–5.
7. Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2. doi:10.1007/s00259-014-2766-y.
8. Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016;41:83–5. doi:10.1097/rlu.0000000000000995.
9. Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82. doi:10.1007/s12149-015-1017-z.
10. Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, et al. [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015;42:56–65. doi:10.1007/s00259-014-2902-8.